Both Pain Therapeutics Inc. (NASDAQ:PTIE) and Ophthotech Corporation (NASDAQ:OPHT) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pain Therapeutics Inc.||N/A||0.00||N/A||-1.16||0.00|
Table 1 highlights Pain Therapeutics Inc. and Ophthotech Corporation’s gross revenue, earnings per share and valuation.
Table 2 represents Pain Therapeutics Inc. (NASDAQ:PTIE) and Ophthotech Corporation (NASDAQ:OPHT)’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Pain Therapeutics Inc.||0.00%||-68.4%||-63.1%|
Volatility & Risk
Pain Therapeutics Inc.’s volatility measures that it’s 94.00% more volatile than Standard & Poor’s 500 due to its 1.94 beta. Competitively, Ophthotech Corporation’s 51.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.51 beta.
The current Quick Ratio of Pain Therapeutics Inc. is 24 while its Current Ratio is 24. Meanwhile, Ophthotech Corporation has a Current Ratio of 13 while its Quick Ratio is 13. Pain Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Ophthotech Corporation.
Insider and Institutional Ownership
Roughly 24.4% of Pain Therapeutics Inc. shares are owned by institutional investors while 65.6% of Ophthotech Corporation are owned by institutional investors. About 0.9% of Pain Therapeutics Inc.’s share are owned by insiders. Comparatively, 0.2% are Ophthotech Corporation’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Pain Therapeutics Inc.||-1.64%||2.56%||8.11%||22.45%||-81.54%||41.18%|
For the past year Pain Therapeutics Inc. was more bullish than Ophthotech Corporation.
On 3 of the 5 factors Pain Therapeutics Inc. beats Ophthotech Corporation.
Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The companyÂ’s lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat AlzheimerÂ’s disease and other neurological disorders. The company was founded in 1998 and is based in Austin, Texas.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.